Biosimilar Antibodies

BT-063 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-10 (IL-10). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.74 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Usilnetug is a human IgG1 κ monoclonal antibody targeting amyloid precursor protein (APP). For control experiments, it is recommended to use Human IgG1 kappa Isotype Control.

Brodalumab (AMG 827) is a humanized IgG2 monoclonal antibody targeting the interleukin-17 receptor. This antibody is utilized in research focused on understanding and treating moderate-to-severe plaque psoriasis and rheumatoid arthritis. Brodalumab's mechanism involves blocking the activity of interleukin-17 (IL-17), a cytokine that plays a critical role in mediating inflammatory and immune responses.

Volrustomig is a human IgG1 κ monoclonal antibody targeting CTLA4 and PDCD1. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Conatumumab (AMG 655) is a human monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2), displaying high affinity with dissociation constants (Kd) of 1 nM for the long form of DR5 and 0.8 nM for the short form. This antibody functions by inducing apoptosis through caspase activation, making it highly relevant for cancer research applications.

Bevacizumab is a humanized IgG1 monoclonal antibody designed to bind with high affinity to all isoforms of vascular endothelial growth factor A (VEGF-A). This specific interaction inhibits the biological activity of VEGF-A, which plays a critical role in angiogenesis and the promotion of tumor growth. Bevacizumab is utilized extensively in research focused on cancer therapy, particularly in studies exploring the mechanisms of angiogenesis inhibition in tumor progression.

The Anti-Fc gamma R1 Antibody is derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells. It specifically targets Fc gamma R1, incorporating a human IgG1 heavy chain and a human kappa light chain. This antibody has a predicted molecular weight of 150 kDa. For isotype control, reference is made to the Human IgG1 kappa, Isotype Control, which is recommended for appropriate experimental comparisons.

VIB-9600 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting FcγR2a/CD32a. This antibody is comprised of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 150 kDa. For experimental controls, the appropriate isotype control is Human IgG1 kappa.

Ciletatug is a humanized IgG1κ monoclonal antibody specifically targeting Claudin 18 (CLDN18). For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Ibramvibart is a human IgG1 κ monoclonal antibody targeting the Spike protein of SARS-CoV-2. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Cixutumumab (IMC-A12) is a human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) with high affinity. It effectively inhibits ligand-dependent activation of the receptor and subsequent downstream signaling pathways. Additionally, Cixutumumab facilitates the internalization and degradation of IGF-1R, contributing to its inhibitory effects. This antibody demonstrates broad-spectrum antitumor activity, making it suitable for research in various cancer types including lung cancer, leukemia, non-small cell lung cancer, and prostate cancer. Cixutumumab is an essential tool for studies exploring the role of the IGF-1R pathway in cancer pathogenesis and therapy.

Brontictuzumab (OMP 52M51) is a monoclonal antibody designed to target and inhibit the Notch1 signaling pathway. This antibody specifically binds to the negative regulatory region of Notch1, a critical component in cell differentiation, proliferation, and apoptotic processes. By inhibiting this pathway, Brontictuzumab effectively impedes tumor cell proliferation, making it a valuable tool in the study of hematological malignancies such as leukemia and lymphoma. Its selective binding affinity and inhibitory action on Notch1 provide a focused approach for researchers investigating the pathological roles of Notch1 signaling in cancer.

Timolumab (BTT1023) is a recombinant, fully human monoclonal antibody designed to specifically target and bind to Vascular Adhesion Protein-1 (VAP-1). This interaction has significant potential for the modulation of immune responses in various chronic inflammatory conditions. Timolumab (BTT1023) is primarily utilized in research focused on elucidating the pathophysiological mechanisms and therapeutic interventions for chronic inflammatory diseases.

Etesevimab (JS016) is a recombinant, fully human, neutralizing monoclonal antibody of the IgG1 subclass, specifically targeting the SARS-CoV-2 virus. This antibody binds with high specificity to the spike protein of SARS-CoV-2, thereby inhibiting the virus's ability to enter host cells and propagate infection. Etesevimab is utilized in research focused on the therapeutic response and viral mechanism of SARS-CoV-2.

Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody designed to inhibit the activity of a proliferation-inducing ligand (APRIL). This antibody selectively suppresses pathogenic immunoglobulins, specifically IgA and IgM, while maintaining effective antibody responses to mRNA-based SARS-CoV-2 vaccines. Additionally, Sibeprenlimab has demonstrated potential in reducing the urinary protein-to-creatinine ratio (UPCR) and stabilizing glomerular filtration rate (GFR), indicating its utility in the investigation of IgA nephropathy (IgAN). This makes Sibeprenlimab a valuable tool for research focused on autoimmune renal disorders and immune response modulation.

Lacnotuzumab (MCS110) is a humanized IgG1/κ monoclonal antibody that selectively targets colony-stimulating factor 1 (CSF-1), effectively blocking its interaction with the CSF-1 receptor (CSF-1R). This neutralization impedes CSF-1R activation, which is crucial in various cellular processes. Lacnotuzumab is primarily utilized in research focused on pigmented villonodular synovitis, providing valuable insights into the pathophysiology and potential therapeutic targets of this disease.

Fresolimumab (GC1008) is a human monoclonal antibody designed to target and neutralize all active mammalian subtypes of Transforming Growth Factor-beta (TGF-β). It exhibits a high binding affinity to TGF-β2, with a dissociation constant (Kd) of 1.8 nM, indicating robust interaction with this cytokine. When conjugated with the radiolabel 89Zr, Fresolimumab serves as a valuable tool for Positron Emission Tomography (PET) analysis, facilitating the study of TGF-β expression, antibody biodistribution, and organ-specific uptake. This antibody is extensively applicable in research focused on cancer, fibrosis, osteogenesis imperfecta, and kidney disease, providing insights into the pathophysiological roles of TGF-β in these conditions.

Xirestomig is a monoclonal antibody targeting TNFRSF9 and CD274. This antibody is designed for specificity against these tumor necrosis factor receptor superfamily member 9 and programmed death-ligand 1 (PD-L1), implicated in immune response modulation. Xirestomig is utilized primarily in research focusing on the mechanisms of immune checkpoint regulation and potential therapeutic interventions in cancer immunotherapy.

Futuximab is a chimeric monoclonal antibody designed to bind specifically to non-overlapping epitopes on the Epidermal Growth Factor Receptor (EGFR). This targeted binding is intended to inhibit the receptor's activity, thereby exerting antineoplastic effects. Futuximab is employed in research focused on the modulation of EGFR function and its role in cancer pathogenesis.

Pemivibart is a human IgG1 λ2 monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental controls, it is recommended to use Human IgG1 lambda2 Isotype Control.

Vonlerizumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target TNFRSF4, also known as OX40 or CD134. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145.22 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Vonlerizumab is applicable in research focused on the modulation of immune responses, particularly in the context of cancer immunotherapy and autoimmune diseases.

Theralizumab (TGN1412) is a humanized IgG4 monoclonal antibody with superagonistic properties targeting CD28. It directly stimulates T-cell activation, which can lead to cytokine release syndrome (CRS). This antibody is primarily utilized in research focused on understanding and potentially treating rheumatoid arthritis.

Alpitatug (IMC 3C5) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target Kallikrein 2 (KLK2). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145.3 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Pamlectabart is a humanized IgG1κ antibody that specifically targets TNFRSF17. For experimental consistency and control, it is recommended to use Human IgG1 kappa as the isotype control.

Icatolimab is a humanized antibody derived from Chinese Hamster Ovary (CHO) cells, specifically designed to target BTLA/CD272. This antibody is comprised of human IgG4SP type heavy chains and human kappa type light chains, exhibiting a predicted molecular weight of 146 kDa. For experimental controls, the corresponding isotype control recommended is Human IgG4 kappa.

Nesvacumab is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) class, designed to selectively target and neutralize the Tie2 receptor ligand Angiopoietin-2 (Ang2). It exhibits high binding affinity specifically for Ang2, without interacting with Angiopoietin-1 (Ang1). This specificity makes it an ideal candidate for research focused on vascular biology and diseases associated with Ang2-mediated signaling pathways.

The Anti-c-Kit Antibody (LMJ729), also known as LOP628 antibody, is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the stem cell factor receptor (SCFR), also recognized as c-Kit or CD117. This antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is designed for the detailed study of c-Kit expression and function in various research applications.

Casirivimab (REGN10933) is a human monoclonal antibody designed to specifically target the SARS-CoV-2 virus, responsible for COVID-19. This antibody has shown limitations in its efficacy against emerging COVID-19 variants. For enhanced therapeutic potential, Casirivimab can be administered in conjunction with Imdevimab. This combination has been demonstrated to modify the pulmonary response in K18-hACE2 transgenic mice infected with the SARS-CoV-2 δ variant, leading to a significant reduction in viral load and amelioration of clinical symptoms.

Anti-AGER/RAGE Antibody (XT-M4) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the receptor for advanced glycation end-products (AGER), also known as RAGE. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

IMC-C103C is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting MAGE-A4, a member of the melanoma antigen family. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This specificity and configuration make IMC-C103C an essential tool for research focusing on cancer biology and immunotherapy involving MAGE-A4.

Calotatug is a human monoclonal antibody of the IgG1κ isotype, specifically designed to target ERBB2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is pivotal in studies focused on the role of ERBB2 in various biological processes and diseases.

MVT-5873 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Sialyl-Lewis A. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of approximately 145.66 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This specificity and configuration make MVT-5873 an essential tool for research focused on the role of Sialyl-Lewis A in various biological processes.

Daratumumab is a pioneering human-specific monoclonal antibody (IgG1) targeting CD38, a surface antigen widely expressed on multiple myeloma (MM) cells. This first-in-class antibody exhibits potent anti-myeloma activity by disrupting cell adhesion, thereby enhancing the susceptibility of MM cells to proteasome inhibitors. Daratumumab serves as a critical tool in the therapeutic arsenal against multiple myeloma, offering a novel mechanism of action that complements existing treatment modalities.

GSK-679586 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Ruzaltatug is a humanized IgG1 monoclonal antibody engineered to specifically target ERBB3, also known as HER3. This receptor is a critical component of the EGFR family, known for its role in promoting tumor growth and conferring resistance to targeted cancer therapies. By binding to ERBB3, Ruzaltatug effectively inhibits key downstream signaling pathways, including PI3K/AKT, thereby potentially reducing cancer cell proliferation and enhancing cell death. Additionally, as a humanized IgG1 antibody, Ruzaltatug is capable of mediating antibody-dependent cellular cytotoxicity (ADCC), adding a mechanism that may contribute to its therapeutic efficacy. Recommended isotype controls for this antibody are Human IgG1 kappa, Isotype Control, to ensure accurate experimental results.

Tinurilimab (Bay 1834942) is a monoclonal antibody targeting CEACAM6, a known immune checkpoint regulator that inhibits the activity of effector T-cells in tumor environments. This antibody is designed for the selective blockade of CEACAM6, facilitating the restoration of immune response against malignant cells. Tinurilimab is pivotal for research focused on immune checkpoint pathways and the development of therapeutic strategies in oncology.

Lasrekibart is a humanized monoclonal antibody designed to selectively target human interleukin 5 (IL-5). By binding specifically to IL-5, Lasrekibart effectively blocks the interaction between IL-5 and its receptor, thereby exerting immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into allergic and inflammatory diseases, including asthma, offering potential insights into disease mechanisms and therapeutic avenues.

The Anti-CD4 Antibody (OKT-4) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human CD4. For accurate experimental control, it is recommended to use Mouse IgG2b kappa as the isotype control. This antibody is ideal for research applications requiring precise targeting of the CD4 protein.

Seniprutug is a human IgG1 κ monoclonal antibody targeting TRBV9. For control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Lusvertikimab (OSE-127) is a humanized monoclonal antibody that targets the interleukin-7 receptor (IL7R). This antibody uniquely binds to IL7R without being internalized by the target cells, effectively inhibiting IL7R heterodimerization and the subsequent downstream signaling pathways. Lusvertikimab demonstrates anti-leukemic properties and holds significant potential for research in B cell precursor acute lymphoblastic leukemia (BCP-ALL), making it a valuable tool for studies aimed at understanding and potentially treating this condition.

Ruplizumab (BG 9588) is a humanized IgG1κ monoclonal antibody targeting CD40 ligand (CD40L), a member of the TNF receptor superfamily. This antibody is designed for the investigation of its therapeutic potential in systemic lupus erythematosus (SLE). Ruplizumab may facilitate the study of CD40L interactions and signaling pathways in immune response regulation, providing insights into the pathogenesis and treatment of SLE.

Nemolizumab (CIM331) is a humanized monoclonal antibody designed to selectively target the interleukin-31 receptor alpha (IL-31RA). By binding to IL-31RA, Nemolizumab effectively inhibits the interaction between interleukin-31 (IL-31) and its receptor, thereby blocking the downstream signaling pathways. This inhibition is clinically relevant as it contributes to the reduction of pruritus (itching) and sleep disturbances associated with various dermatological conditions, including atopic dermatitis (AD). Nemolizumab is currently under investigation for its therapeutic potential and efficacy in treating symptoms of AD and related conditions.

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based bispecific antibody (BsAb) designed to target the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells, as well as CD3 on T cells. This dual targeting promotes efficient synapse formation between T cells and MM tumor cells, enhancing the cytotoxic activity of T cells against the tumor cells. Cevostamab's unique mechanism of action makes it a valuable tool for research in immuno-oncology and the therapeutic targeting of multiple myeloma.

Ficlatuzumab is a monoclonal antibody specifically designed to target human hepatocyte growth factor (HGF). This antibody effectively blocks the activation of the HGF/c-Met signaling pathway, crucial in modulating processes such as cell proliferation, migration, and invasion associated with cancer progression. By inhibiting the c-Met receptor-mediated activities, Ficlatuzumab serves as a potent therapeutic agent in the study and potential treatment of various cancers characterized by overactivation of this pathway.

Lafuvitug (3BNC-117) is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the HIV-1 envelope glycoprotein gp120. This interaction is crucial for blocking the virus's ability to attach to and enter host cells, thus inhibiting viral replication. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody designed to inhibit IL-33 signaling through specific binding to ST2, the receptor for IL-33. This antibody is primarily explored for its therapeutic potential in studies related to chronic obstructive pulmonary disease (COPD), offering a targeted approach to modulate immune responses implicated in this condition.

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody specifically designed to target sialic acid-binding Ig-like lectin 8 (SIGLEC8). This antibody promotes apoptosis in interleukin-5 (IL-5)-activated eosinophils and effectively inhibits immunoglobulin E (IgE)-mediated mast cell activation. Lirentelimab is primarily utilized in research focused on eosinophilic gastritis and duodenitis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.

The Anti-BACE1 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target BACE1 (beta-site APP-cleaving enzyme 1). This antibody has a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focused on Alzheimer's disease and other neurological disorders, where BACE1 plays a critical role in amyloid-beta peptide production.